CRISPR Therapeutics has exciting gene-editing candidates in the works. Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) are two incredibly innovative biotechs ...

Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can’t seem to catch a break, now down close to 8% year to date and more than 80% from now-distant 2021 all-time highs.The gene-editing innovator is at ...

CRISPR Therapeutics won its first regulatory approval a little over a year ago, and has compelling candidates in the pipeline. Of course, Vertex's success didn't happen overnight -- and the ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $34.26, marking a -1.81% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.46%.

Two stocks she likes: Crispr Therapeutics, which uses the Crispr technology to treat diseases caused by genetic mistakes; and Tempus AI, which uses AI and electronic health records to help ...

While CRISPR-mediated gene editing has led to powerful advances across biology, medicine, and agriculture, challenges persist in optimizing the editing efficiency of enzymes, such as the widely ...